Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin for Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck

Open-Label, Multicenter, Phase Ⅱ Study Of Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin As First-Line Treatment In Patients With Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck

The purpose of this single arm, phase Ⅱ clinical trail is to determine the safety and efficacy of paclitaxel (albumin bound),bleomycin and cisplatin or carboplatin in the treatment of recurrent Or metastatic squamous cell carcinoma of the head and neck

Inclusion Criteria:

• biopsy proved squamous cell carcinoma of the head and neck;
• stage IVc according to Union for International Cancer Control (UICC) edition VIII, or recurrent disease after chemotherapy and/or radiotherapy;
• 18 years or older; without other malignancy;
• proper functioning of the major organs.

Exclusion Criteria:

• allergic to paclitaxel (albumin bound) or bleomycin or cisplatin or carboplatin ;
• female within gestation period or lactation;
• patients received drug of other clinical trial within 3 months